Cite
HARVARD Citation
Delaloge, S. et al. (2022). Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. European journal of cancer. pp. 300-308. [Online].